San Diego Biotech Iambic Therapeutics Filed for IPO

The San Diego-based drug discovery firm has moved to go public following a recent partnership deal.

Updated on Sept. 22, 2026 in Biotech

Isometric editorial illustration showing a complex molecular model structure on a laboratory surface, representing biotechnology drug discovery. — Iambic Therapeutics has filed for an initial public offering with the Securities and Exchange Commission, aiming to fund its clinical drug trials. AI Illustration. Upload story photo >

Live Poll

Do you trust AI-driven biotechnology companies to successfully develop new medical treatments?

Iambic Therapeutics has officially filed for an initial public offering with the Securities and Exchange Commission. The San Diego firm, which uses its AI-based platform NeuralPLexer to discover new drugs, intends to use the capital to fund clinical trials.

Why it matters

The move to public markets allows the biotech to raise significant capital necessary for high-cost clinical development. Specifically, the company is prioritizing the advancement of its drug candidate IAM1363.

The company employs 171 full-time staff and utilizes its proprietary NeuralPLexer AI platform to support drug discovery. Its pipeline includes drug candidates IAM1363, IAM217, and IAM-C1.

The players

Iambic Therapeutics

This San Diego-based biotechnology company focuses on AI-driven drug discovery for complex medical challenges.

AbbVie

AbbVie is a global research-driven biopharmaceutical company that recently entered into a partnership with Iambic Therapeutics.

The details

Founded in 2019, Iambic Therapeutics has grown through multiple funding rounds and strategic partnerships, including a recent agreement with AbbVie. The company plans to move several candidates into clinical testing, with a registrational trial for IAM1363 expected to launch in early 2027.

Iambic Therapeutics was founded in 2019.
The company held $207.9 million in cash on June 30, 2026.
AbbVie signed a partnership deal on September 21, 2026.
Iambic Therapeutics filed for an IPO on September 21, 2026.
A registrational trial for IAM1363 is planned for early 2027.

The Tech Race

This filing reflects the broader shift toward integrating AI-based drug discovery platforms like NeuralPLexer into traditional pharmaceutical pipelines. It positions Iambic Therapeutics to compete by accelerating the development of specialized clinical candidates.

For the biotechnology sector, the IPO signals potential changes in clinical research speed and drug development availability. Investors and patients should watch for updates on trial progress as the company scales its operations.

The takeaway

Iambic Therapeutics is leveraging its AI technology to move from private funding rounds to a public company status. This transition is aimed at securing the financial runway needed to push clinical-stage drug candidates through human testing.